Literature DB >> 28944183

Transaortic septal myectomy: techniques and pitfalls.

Anthony Ralph-Edwards1, Rachel D Vanderlaan1, Pietro Bajona2,3.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common congenital cardiac disease, affecting up to 1 in 200 individuals. When it causes left ventricular outflow tract (LVOT) obstruction, treatment is indicated to reduce symptoms and the risk of sudden cardiac death. Pharmacologic therapy is the first line treatment, however if it fails, surgical myectomy or percutaneous ablation of the hypertrophic myocardium are the standard therapies to eliminate subaortic obstruction. Both surgical myectomy and percutaneous ablation have been demonstrated as safe and effective treatments; however, myectomy is the gold standard with a significantly lower complication rate and more complete and longstanding reduction of LVOT obstruction.

Entities:  

Keywords:  Hypertrophic obstructive cardiomyopathy; septal myectomy; surgical technique

Year:  2017        PMID: 28944183      PMCID: PMC5602211          DOI: 10.21037/acs.2017.07.08

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  4 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12       Impact factor: 5.209

2.  Short and medium term outcomes of surgery for patients with hypertrophic obstructive cardiomyopathy.

Authors:  Dominic J Parry; Robert E Raskin; Jeffery A Poynter; Igo B Ribero; Pietro Bajona; Harry Rakowski; Anna Woo; Anthony Ralph-Edwards
Journal:  Ann Thorac Surg       Date:  2015-02-10       Impact factor: 4.330

3.  Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy.

Authors:  J M ten Berg; M J Suttorp; P J Knaepen; S M Ernst; F E Vermeulen; W Jaarsma
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

4.  Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy.

Authors:  B J Maron; S E Epstein; A G Morrow
Journal:  Eur Heart J       Date:  1983-11       Impact factor: 29.983

  4 in total
  2 in total

1.  Phenylephrine Provocation to Evaluate the Cause of Mitral Regurgitation in Patients With Obstructive Hypertrophic Cardiomyopathy.

Authors:  Jonathan D Moreno; Richard G Bach; Ralph J Damiano; Sara C Martinez; Sharon Cresci
Journal:  Circ Cardiovasc Imaging       Date:  2021-05-04       Impact factor: 7.792

2.  Proteomic mapping of atrial and ventricular heart tissue in patients with aortic valve stenosis.

Authors:  Boris Barbarics; Katja Eildermann; Lars Kaderali; Lukas Cyganek; Uwe Plessmann; Julius Bodemeyer; Thomas Paul; Philipp Ströbel; Henning Urlaub; Theodorus Tirilomis; Christof Lenz; Hanibal Bohnenberger
Journal:  Sci Rep       Date:  2021-12-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.